Pterygium: Etiology, clinical aspects and novel adjuvant therapies;Pterygium: Ätiologie, Klinik und neueadjuvante Therapien

Ophthalmologe

Volumn 107, Issue 6, 2010, Pages 517-524

  Heindl, L M ^a   Cursiefen, C ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Bevacizumab; Mitomycin C; Pterygium; Recurrence; Ultraviolet light protection

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CORTICOSTEROID; MITOMYCIN; MONOCLONAL ANTIBODY;

ARTICLE; CONJUNCTIVA; DIFFERENTIAL DIAGNOSIS; EYE; EYE PROTECTIVE DEVICE; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PTERYGIUM; RADIATION EXPOSURE; RADIATION INJURY; RECURRENT DISEASE; TRANSPLANTATION; ULTRAVIOLET RADIATION;

ADRENAL CORTEX HORMONES; ALKYLATING AGENTS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; CONJUNCTIVA; DIAGNOSIS, DIFFERENTIAL; EYE; EYE PROTECTIVE DEVICES; HUMANS; MITOMYCIN; PTERYGIUM; RADIATION INJURIES; RECURRENCE; ULTRAVIOLET RAYS;

EID: 77954027841     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-009-2100-4     Document Type: Article

References (32)

1. Ang LP, Chua JL, Tan DT (2007) Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol 18: 308-313.
2. Bahar I, Kaiserman I, McAllum P et al (2008) Subconjunctival bevacizumab injection for corneal neovascularisation in recurrent pterygium. Curr Eye Res 33: 23-28.
3. Bock F, König Y, Kruse F et al (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246: 281-284.
4. Bock F, Onderka J, Rummelt C et al (2009) Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 50: 2095-2102.
5. Bradley JC, Yang W, Bradley RH et al (2009) The science of pterygium. Br J Ophthalmol, Epub ahead of print.
6. Chui J, Di Girolamo N, Wakefield D, Coroneo MT (2008) The pathogenesis of pterygium: current concepts and their therapeutic implications. Ocul Surf 6: 24-43.
7. Cursiefen C (2009) Bevacizumab goes anterior: antiangiogenic therapy at cornea and conjunctiva. Ophthalmologe 106: 397-398.
8. Cursiefen C, Bock F, Horn FK et al (2009) GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology 116: 1630-1637.
9. Cursiefen C, Kruse FE, Naumann GOH (2008) Conjunctiva and limbus corneae. In: Naumann GOH, Holbach L, Kruse FE (eds) Applied pathology for ophthalmic microsurgeons. Springer, Berlin Heidelberg, pp 67-75.
10. Di Girolamo N, Chui J, Coroneo MT et al (2004) Pathogenesis of pterygia: role of cytokines, growth factors and matrix metalloproteinases. Prog Retin Eye Res 23: 195-228.
11. Gebhardt M, Mentlein R, Schaudig U et al (2005) Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology 112: 1023-1030.
12. Hirst LW (2003) The treatment of pterygium. Surv Ophthalmol 48: 145-180.
13. Hirst LW, Axelsen RA, Schwab I (2009) Pterygium and associated ocular surface squamous neoplasia. Arch Ophthalmol 127: 31-32.
14. Ibáñez M, Eugarrios MF, Calderón DI (2009) Topical cyclosporin A and mitomycin C injection as adjunctive therapy for prevention of primary pterygium recurrence. Ophthalmic Surg Lasers Imaging 40: 239-244.
15. Kim SW, Ha BJ, Kim EK et al (2008) The effect of topical bevacizumab on corneal neovascularisation. Ophthalmology 115: e33-e38.
16. Kim TI, Chung JL, Hong JP et al (2009) Bevacizumab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci 50: 4653-4659.
17. Kruse FE, Meller D (2001) Amniotic membrane transplantation for reconstruction of the ocular surface. Ophthalmologe 98: 801-810.
18. Kruse FE, Völcker HE, Naumann GOH (1997) Konjunktiva. In: Naumann GOH (Hrsg) Pathologie des Auges. Springer, Berlin Heidelberg, S 379-506.
19. Leippi S, Grehn F, Geerling G (2009) Antiangiogenic therapy for pterygium recurrence. Ophthalmologe 105: 413-419.
20. Lim R, Mitchell P, Cumming RG (1998) Cataract associations with pinguecula and pterygium: the Blue Mountains Eye Study. Am J Ophthalmol 126: 717-719.
21. Moran DJ, Hollows FC (1984) Pterygium and ultraviolet radiation: a positive correlation. Br J Ophthalmol 68: 343-346.
22. Paris Fdos S, Farias CC de, Melo GB et al (2008) Postoperative subconjunctival corticosteroid injection to prevent pterygium recurrence. Cornea 27: 406-410.
23. Pham TQ, Wang JJ, Rochtchina E, Mitchell P (2005) Pterygium/pinguecula and the five-year incidence of age-related maculopathy. Am J Ophthalmol 139: 536-537.
24. Regenfuss B, Bock F, Bachmann B et al (2009) Topical inhibition of angiogenesis at the cornea. Safety and efficacy. Ophthalmologe 106: 399-406.
25. Rubinfeld RS, Pfister RR, Stein RM et al (1992) Serious complications of topical mitomycin-C after pterygium surgery. Ophthamology 99: 1647-1654.
26. Sekundo W, Droutsas K, Cursiefen C (o J) Operative Techniken bei chirurgischer Behandlung primärer und rezidivierender Pterygien. Ophthalmologe (dieses Heft).
27. Soriano JM, Janknecht P, Witschel H (1993) Effect of pterygium operation on preoperative astigmatism. Prospective study. Ophthalmologe 90: 688-690.
28. Ti SE, Tseng SC (2002) Management of primary and recurrent pterygium using amniotic membrane transplantation. Curr Opin Ophthalmol 13: 204-212.
29. Tsai YY, Chiang CC, Bau DT et al (2008) Vascular endothelial growth factor gene 460 polymorphism is associated with pterygium formation in female patients. Cornea 27: 476-479.
30. Vastardis I, Pajic B, Greiner RH et al (2009) Prospective study of exclusive strontium-/yttrium-90 beta-irradiation of primary and recurrent pterygia with no prior surgical excision. Clinical outcome of long-term follow-up. Strahlenther Onkol 185: 808-814.
31. Wu PC, Kuo HK, Tai MH, Shin SJ (2009) Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 28: 103-104.
32. Young AL, Tam PM, Leung GY et al (2009) Prospective study on the safety and efficacy of combined conjunctival rotational autograft with intraoperative 0, 02% mitomycin C in primary pterygium excision. Cornea 28: 166-169.